Adverse effects of proton pump inhibitors
- 1 November 2018
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Opinion in Gastroenterology
- Vol. 34 (6), 451-457
- https://doi.org/10.1097/mog.0000000000000471
Abstract
The present review summarizes the past year's literature, both clinical and basic science, regarding potential adverse effects of proton pump inhibitors. Proton pump inhibitors are amongst the most widely prescribed and overprescribed medications worldwide. Although generally considered well tolerated, epidemiologic studies mining large databases have reported a panoply of purported serious adverse effects associated with proton pump inhibitors, including chronic kidney disease, cognitive decline, myocardial infarction, stroke, bone fracture and even death. It should be noted that the quality of the evidence underlying these associations is very low and these studies, by design, cannot ascribe cause and effect. Nonetheless, these associations have been sensationalized in the media and misinterpreted by patients and providers. Unintended consequences of the fake news are that patients are not being prescribed and/or taking clinical guideline-recommended proton pump inhibitors to prevent and treat complications from gastroesophageal reflux disease and upper gastrointestinal bleeding precipitated by NSAIDs and dual antiplatelet therapies. In addition, physicians, who already have limited time to interact with their patients, are spending an inordinate amount of additional time placing these findings into proper perspective and reassuring their patients when initiating treatment as well as on every follow-up visit. Most of the recent highly publicized serious adverse effects ascribed to proton pump inhibitors are not based on demonstrable evidence. Nevertheless, when proton pump inhibitors are prescribed long-term, they should be used at the lowest effective dose and the need for their use periodically reassessed.Keywords
This publication has 43 references indexed in Scilit:
- Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal CancerJAMA Oncology, 2017
- Zinc Ions Mediate Gastrin Expression, Proliferation, and Migration Downstream of the Cholecystokinin-2 ReceptorEndocrinology, 2016
- Gastrin and upper GI cancersCurrent Opinion in Pharmacology, 2016
- Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real‐world cohort studyHepatology, 2016
- We Are Using Too Many PPIs, and We Need to Stop: A European PerspectiveAmerican Journal Of Gastroenterology, 2016
- Gastrin stimulates a cholecystokinin-2-receptor-expressing cardia progenitor cell and promotes progression of Barrett's-like esophagusOncotarget, 2016
- Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing AgentsAmerican Journal Of Gastroenterology, 2016
- Proton pump inhibitors use and change in bone mineral densityInternational Journal of Rheumatic Diseases, 2016
- A comparison of the gut microbiome between long‐term users and non‐users of proton pump inhibitorsAlimentary Pharmacology & Therapeutics, 2016
- Heterogeneous expression of cholecystokinin and gastrin receptor in stomach and pancreatic cancer: An immunohistochemical studyJournal of Cancer Research and Therapeutics, 2016